International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494

Genetic Related ADR in Specific Population a Study of Lietrature

Prof.(Dr.) Mohd Wasiullah[1],Prof.(Dr.) Piyush Yadav[2],Mr. MohitVishwakarma*[3],Amina Ahsan[4]

Date of Submission: 25-04-2025 Date of Acceptance: 05-05-2025

ABSTRACT
Adverse drug reactions (ADRs) are a significant cause of morbidity and mortality worldwide, with genetic susceptibility playing a crucial role in determining individual responses to medications. Pharmacokinetics', a branch of clinical genetics, focuses on how genetic variations affect drug responses. This report highlights the impact of genetic factors on ADRs, emphasizing the role of genetic polymorphisms in drug metabolism, transport, and immune responses. Specific genetic variants, such as those in HLA genes, CYP enzymes, and drug transporters, can significantly influence an individual's risk of experiencing ADRs. Understanding these genetic factors can help personalize treatment strategies, minimizing ADRs and optimizing drug efficacy. The integration of genetic insights into medical practice has the potential to revolutionize patient care, enabling healthcare providers to tailor treatments to individual genetic profiles. This approach can reduce the burden of ADRs on patients and the healthcare system, promoting more effective and safer treatments.

KEYWORDS: Genetic , ADR, Pharmacogenomics, Genetic Factors, pharmacovigilance ADR,

I. INTRODUCTION

Adverse drug reactions (ADRs) are a significant cause of illness and death worldwide, with genetic susceptibility being a growing concern in various medical fields. Pharmacogenetics, a branch of clinical genetics, focuses on how variations in genes affect the response to medications.

Around 80% of patients may have genetic variations that influence the effectiveness of commonly prescribed drugs. Preemptive PGx testing, which analyzes an individual's genetic profile before prescribing medications, can help minimize ADRs and enhance drug effectiveness. Research indicates that at least 30% of ADR-related hospital admissions were linked to drugs with clinical annotations in the Pharmacogenomics Knowledge Base. This approach can help identify patients at risk of adverse reactions and optimize medication choices for better efficacy and tolerability.

Pharmacogenetics integrates genetic insights into medical practice to reduce the burden of adverse drug reactions (ADRs) on patients and the healthcare system. This report provides an update on genetic factors contributing to ADRs and highlights key indicators for clinical decision-making.[1] The expansion of genetic testing and advancements in artificial intelligence could promote personalized medicine, enabling the prediction of ADRs and the selection of safer drugs and dosages. ADRs have severe clinical and financial consequences, contributing to over 100,000 deaths annually in the US.

Definition of adverse drug reactions

ADRs, defined by the World Health Organization and the European Medicines Agency, are untoward medical occurrences in patients or clinical trial subjects administered a medicinal product. They occur at doses normally used for disease prophylaxis, diagnosis, or therapy. In 2010, the European Union expanded this definition to include medication errors and off-label uses.[2]

According to the Food and Drug Administration (FDA), an ADR is defined as "any noxious, unintended and undesired effect of a drug, which occurs at doses used in humans for prophylaxis, diagnosis, or therapy." This definition excludes therapeutic failures, intentional or accidental poisoning, and drug abuse.[3]Additionally, the FDA differentiates between ADRs and adverse events, defining the latter as "any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.

ADRs arise through various mechanisms, and they are categorized into two main types, each with potential implications for treatment strategies:

- Type A reactions are predictable and milder due to an excessive dose of a drug, influenced by enzyme proteins. They have lower mortality rates and are associated with pharmacokinetics

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494

and pharmacodynamics. This has led to the emergence of "pharmacogenetics," a field that examines genetic variations affecting drug metabolism to improve treatment strategies and prevent ADRs.

- Type B reactions are less frequent and unpredictable, often linked to genetic conditions, and may result from altered pharmacokinetics or modified pharmacodynamic properties.

Pharmacovigilance of Genetic-Related ADRs in Specific Populations

Pharmacovigilance plays a crucial role in ensuring drug safety by monitoring and evaluating adverse drug reactions (ADRs). One of the most significant aspects of pharmacovigilance is identifying genetic-related ADRs, which can vary across different populations due to genetic diversity. Certain genetic polymorphisms can influence drug metabolism, efficacy, and toxicity, leading to variable responses to medications. Therefore, understanding the genetic basis of ADRs in specific populations is essential to optimize drug therapy and enhance patient safety.[4]

- **Genetic Polymorphisms and Drug Metabolism:** Genetic polymorphisms in drug-metabolizing enzymes, transporters, and receptors significantly impact an individual's response to medications. Variations in CYP genes, such as CYP2C19, CYP2D6, and CYP3A4, can lead to altered drug metabolism, causing severe toxicity or subtherapeutic effects. Pharmacogenetic testing can reduce adverse drug reactions and improve treatment outcomes.
- **Population-Specific Variations in Genetic ADRs:** Ethnic populations have unique genetic variations that affect drug responses. For instance, the HLA-B*15:02 allele in Southeast Asians is linked to severe cutaneous ADRs, while the HLA-B*57:01 allele is linked to hypersensitivity reactions to abacavir. CYP2C19 polymorphisms also vary among populations, with East Asians being poor metabolizers of clopidogrel, increasing cardiovascular events, and Europeans having more normal metabolizers.
- **Role of Pharmacovigilance in Genetic-Related ADRs:**Pharmacovigilance systems are crucial for detecting, reporting, and managing genetic-related adverse drug reactions (ADRs). Regulatory agencies like FDA, EMA, and PMDA use pharmacogenetic labeling for drug testing recommendations.[5]Adverse event reporting databases like VigiBase help identify ADRs.

Pharmacovigilance of genetic-related ADRs is an evolving field that holds great promise for enhancing drug safety and treatment efficacy. Understanding genetic polymorphisms and their impact on drug metabolism is essential for tailoring therapy to individual patients, particularly in populations with high genetic susceptibility to ADRs. Strengthening pharmacovigilance systems, improving genetic screening accessibility, and fostering global collaboration will be key to advancing precision medicine and reducing the burden of genetic-related ADRs in diverse populations.

Genetic-Related Adverse Drug Reactions (ADRs) in Specific Populations

Genetic-related ADRs vary significantly across different populations due to genetic polymorphisms influencing drug metabolism.[6] Studies have shown that certain ethnic groups are more susceptible to specific ADRs due to variations in drug-metabolizing enzymes like CYP450, TPMT, and HLA alleles. For example, individuals of East Asian descent have a higher prevalence of the HLA-B1502 allele, making them more prone to severe cutaneous adverse reactions (SCARs) like Stevens-Johnson Syndrome (SJS) with carbamazepine. Similarly, African populations have a higher frequency of G6PD deficiency, increasing their risk of hemolysis with drugs like primaquine. European populations show variations in CYP2D6 affecting codeine metabolism, leading to ultra-rapid or poor metabolism-related ADRs.[7]

A study analyzing genetic ADRs experiencen different ethnic groups found that East Asians experienceed higher rates of SJS/TEN, while Europeans exhibited a higher incidence of warfarin sensitivity due to VKORC1 and CYP2C9 variants. Understanding such population-specific risks is crucial for personalized medicine and optimizing drug safety.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494



Figure 2: Graph showing the prevalence of genetic-related ADRs across different populations. It shows specific genetic polymorphisms influence drug reactions in East Asians, Africans, Europeans, South Asians, and Latinos.

Role of Genetic Codification in Adverse Drug Reactions

ADRs may have a familial tendency, but a clear Mendelian inheritance pattern isn't observed. Genetic mutations suggest a predisposition, but not a definitive prediction. ADRs can occur in individuals with variants of uncertain significance.[8]

Genetic information is encoded in complex molecules like genomic DNA, mitochondrial DNA, and RNA. The genetic code directs the synthesis of amino acids, contributing to cellular functions. Understanding the genetic basis of ADRs requires understanding the relationship between genetic information and environmental influences.

Genetic variability is inherited across generations, potentially introducing further complexity.A gene is a DNA sequence within genomic DNA, with two copies of non-sex-linked alleles. Alleles are genetic variants with a frequency below 1% in the general population, excluding inbreeding. Mutations are variants associated with specific pathological phenotypes.Single Nucleotide Polymorphisms (SNPs) are genetic variations affecting ADR risk, with regulatory RNAs playing a significant role in drug response, affecting over 1% of the population.[9]

In pharmacogenetics, key variants and SNPs are denoted with an asterisk. A "haplotype" refers to the specific arrangement of variants or SNPs along a gene. The significance of haplotypes in pharmacogenetics arises from the interactions between coding and non-coding genetic sequences.[10]

Genes can encode one or more messenger RNAs (mRNAs), which may either direct protein synthesis or serve regulatory functions. The discovery of a vast array of non-coding RNAs has reshaped traditional gene definitions, revealing overlapping biological functions and highlighting the clinical relevance of genetic regulation.

A recent study examined the role of microRNAs (miRNAs), which are 18–22 nucleotide RNA molecules that regulate the expression of multiple protein-coding genes at the post-transcriptional level.[11]

MiRNAs influence drug responses by modulating genes involved in pharmacokinetics and pharmacodynamics. Variations in circulating miRNA levels or genetic differences in miRNA sequences contribute to individual differences in drug toxicity and efficacy.

Due to their stability in body fluids, ease of collection, and precise quantification, miRNAs have potential as biomarkers for predicting individual drug responses.[12]

Role of Metabolism in Adverse Drug Reactions

Genetic mutations and health conditions like heart failure, diabetes, and cancer increase susceptibility to adverse drug reactions (ADRs), as compromised renal and hepatic metabolism reduces

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494

the body's ability to clear drugs.Beyond these factors, immune system responses play a crucial role in ADR predisposition.[13] There are four main types of immunological drug reactions immediate IgE-mediated hypersensitivity, IgG-mediated responses, serum sickness, and delayed-type cell-mediated reactions. Moreover, both genetic and immunological factors can interact in ADR development, particularly through specific alleles in HLA genes.

Although a detailed discussion of these modulators is outside the scope of this report, it is important to note that drug metabolism is influenced not only by disease-specific genetic mutations but also by environmental factors such as age and exposure to pollutant

Genetic Factors of Severe Adverse Drug Reactions

Currently, genetic biomarkers associated with severe ADRs have been identified, particularly focusing on variants in human leukocyte antigens (HLA), T cell receptors (TCR), drug-metabolizing enzymes, and drug transporters.[16]The U.S. Food and Drug Administration (FDA) has now included genetic information on over 180 approved drugs to guide safer and more effective treatments.

- **Human Leukocyte Antigens:** Type B idiosyncratic reactions are caused by excessive activation of CD4+ and CD8+ T-lymphocytes, with HLA molecules playing a key role in presenting these antigens. High polymorphism in HLA molecules allows for diverse drug interactions, leading to severe adverse reactions (ADRs).[17]

Carbamazepine (CBZ), an aromatic antiepileptic drug, is a well-known cause of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) across various ethnic groups. HLA-B15:02, HLA-A31:01, and HLA-B*57:01 have been linked to severe ADRs.

Oxcarbazepine (OXC), a similar antiepileptic drug, has been linked to SJS/TEN in individuals with HLA-B15:02 alleles. Asian patients with HLA-B15:02, HLA-B13:01, and HLA-B51:01 alleles are at an elevated risk of phenytoin-induced SCAR. Allopurinol, a xanthine oxidase inhibitor, is a common trigger for SJS/TEN.[18]

Abacavir, an antiretroviral medication, has been linked to hypersensitivity reactions associated with HLA-B57:01 in various populations. HLA-A32:01 is a significant risk factor for vancomycin-induced DRESS in European ancestry. Amoxicillin-clavulanate (AC) is a common cause of DILI, affecting 10-13% of patients. Both HLA class I and II alleles contribute to susceptibility to AC-induced DILI.

DILI is a common cause of liver injury, linked to various factors such as lumiracoxib, flucloxacillin, pazopanib, abacavir hypersensitivity, and CBZ-induced SJS/TEN.[19] HLA-B57:01 is a significant risk allele for severe ADRs, including SCAR and DILI, among European populations. HLA-B14:01 is strongly associated with co-trimoxazole-induced DILI in European Americans, while HLA-B35:01 is relevant in African Americans.[20]

- **T Cell Receptors:** Studies have shown the role of specific T-cell receptors (TCRs) in the development of severe adverse drug reactions (ADRs). A public TCR with a CDR3 sequence "VFDNTDKLI" was identified in clonotypes from CBZ-induced SJS/TEN patients, providing insight into how individuals with different HLA alleles can experience similar hypersensitivity reactions. The identification of HLA genetic predispositions and TCR usage supports the theory of an immune synapse.[21]

Adverse Drug Reactions in Different Disease Conditions

The influence of genetics on drug metabolism has been recognized since the identification of glucose-6-phosphate dehydrogenase (G6PD) deficiency.[27]This condition, commonly referred to as “favism,” results in hemolytic anemia following the consumption of fava beans. Over time, additional links have been discovered between hemolytic anemia and the ingestion of other foods, such as beans and peas, as well as the use of specific drugs.[28]

Several other conditions are classically associated with ADRs, including malignant hyperthermia, Lyell syndrome, Stevens-Johnson syndrome, porphyria, Fanconi syndrome, Long QT syndrome, and Brugadasyndrome.Advances in genetic testing, particularly with Next Generation Sequencing (NGS), have helped define the genetic basis of these conditions. This growing body of knowledge has provided two crucial insights for clinical practice: first, different types of ADRs may share a common genetic foundation, and second, even widely occurring genetic polymorphisms can

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494

significantly contribute to ADR development, particularly in older adults.[29]

1.Drug Induced Haemolytic and Aplastic Anaemias

Among drug-induced anemias, the most significant types include hemolytic, sideroblastic, and aplastic anemia. The most frequently observed condition leading to drug-induced hemolytic anemia is glucose-6-phosphate dehydrogenase (G6PD) deficiency.[30]

- **Glucose-6-Phosphate Dehydrogenase Deficiency:**G6PD deficiency, caused by an X-linked mutation, is the most common enzyme deficiency in humans, affecting nearly half a billion individuals globally. This deficiency disrupts the pentose phosphate pathway, causing functional impairment in red blood cells.

G6PD deficiency is diagnosed through laboratory tests, and most individuals do not show symptoms. However, exposure to certain drugs or infections can trigger oxidative stress, leading to NADPH depletion and an acute hemolytic crisis.[31]G6PD deficiency should be considered in patients experiencing acute hemolysis after exposure to known oxidative drugs. Molecular analysis can detect known G6PD gene mutations, with V68M and N126D being the most frequent.

Since the identification of G6PD deficiency, numerous other genetic syndromes and variants have been linked to adverse drug reactions (ADRs) through genome sequencing and linkage analysis.[32]Apart from G6PD deficiency, which is further explored in the context of hemolytic anemias, several other well-documented genetic conditions are associated with ADRs, the most notable being malignant hyperthermia.[33]

- **Aplastic Anaemia:**Fanconi anemia is a genetic disorder caused by drug exposure and is the leading cause of adult-onset aplastic anemia. It involves 19 gene products and increases the risk of bone marrow failure in patients exposed to replicative cell stress. Germline mutations in Fanconi anemia genes make cells sensitive to interstrand crosslinks, obstructing cellular processes and increasing cancer risk.[34]

2.Drug Induced Epilepsy

Epilepsy diagnosis is complex due to its diverse phenotypes and underlying causes, including drug-induced seizures. Over 9% of epilepticus cases are due to drug exposure. Experimental studies since 2019 have provided new insights into genetic predisposition to drug-induced seizures.[35] Researchers investigated Donepezil's effects on Dravet syndrome and Huperzine-A's potential to prevent seizures, suggesting translation to humans could help mitigate side effects.

3.Drug Induced Liver Diseases

Drug-induced liver injury (DILI) is the main cause of acute liver failure in Western countries. Genetic susceptibility to DILI is influenced by HLA genes, with variants like HLA-DRB115:01, HLA-DQB106:02, HLA-A02:01, and HLA-B18:01 increasing risk. Other HLA variants are linked to DILI triggered by drugs like flucloxacillin, minocycline, lumiracoxib, lapatinib, ximelagatran, and ticlopidine.[36]

5.Diabetes and Adverse Drug Reactions

Maturity-onset diabetes of the young (MODY) is a genetic condition causing various phenotypes and influencing treatment approaches. Identifying the genetic basis of diabetes is crucial as incorrect treatment can lead to complications like hyperglycemic hyperosmolar syndrome or severe hypoglycemia. Some forms of MODY can be managed with dietary adjustments, while others respond well to insulin or oral antidiabetic medications.[37]

Current Trends and Future Perspectives

The growing body of literature on severe adverse drug reactions (ADRs) has increasingly highlighted the role of genetic polymorphisms.Advanced sequencing technologies such as whole genome sequencing (WGS) and whole exome sequencing (WES) have significantly accelerated the identification of genetic variants, revolutionizing the field of genetic biomarker research. Pharmacogenetic testing, whether conducted reactively or preemptively, has proven to improve treatment outcomes. Studies indicate that reactive testing helps explain or predict patient responses to drugs during treatment, while preemptive testing can prevent severe ADRs before they occur. Furthermore, numerous studies support the cost-effectiveness of pharmacogenetic testing,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2602-2610 www.ijprajournal.com ISSN: 2456-4494

showing that it reduces overall healthcare costs by preventing life-threatening ADRs.[38]

Pharmacogenetic testing requires standardized protocols, healthcare professionals' expertise, financial resources, data integration, multidisciplinary approach, and increased awareness among physicians. It's crucial for personalized and precision medicine.[39]

Future Prospects of Genetic-Related ADR Research

1. **Widespread Implementation of PharmacogeneticTesting:**Affordable sequencing technologies will integrate preemptive genetic testing into clinical practice, with initiatives like CPI and PharmGKB providing guidelines for optimizing drug therapy.[40]
2. **Artificial Intelligence (AI) and Big Data in ADR Prediction:**AI-driven models will analyze genetic, demographic, and clinical data to predict individual ADR risks.Machine learning approaches will enhance pharmacovigilance by identifying novel genetic markers linked to ADRs.[41]
3. **Development of Population-Specific Drug Dosing Guidelines:**Dosing regimens in non-European populations are suboptimal due to Western trials, requiring future studies to consider ethnic-specific genetic differences for improved drug safety.
4. **Expansion of Pharmacogenetic Research in Understudied Populations:**Pharmacogenomic studies predominantly study Caucasian and East Asian populations, neglecting Indigenous, Latin American, and African populations, necessitating future research to ensure equitable access to pharmacogenomics-based therapies.[42]
5. **Gene Editing and Personalized Medicine:**CRISPR-based gene editing could correct genetic variants causing severe adverse drug reactions, paving the way for precision medicine and personalized drug formulations to reduce risks and improve therapeutic outcomes.[43]

Challenges and Ethical Considerations

Despite the promise of pharmacogenomics, several challenges remain:

1. **Cost and Accessibility:**Genetic testing is still expensive in many parts of the world, limiting widespread implementation.[44]
2. **Ethical Concerns:**Issues of genetic discrimination and privacy need to be addressed before integrating pharmacogenomics into standard care.
3. **Regulatory Hurdles:**Standardizingpharmacogenomic guidelines across different healthcare systems remains.[45]

II. CONCLUSION

Adverse drug reactions (ADRs) are often misdiagnosed and underestimated, despite being a significant contributor to morbidity and mortality. Genetic testing has helped identify genes associated with ADRs, potentially reducing mortality rates and healthcare expenses. However, the number of drugs available for pharmacogenetic testing is limited. ADRs can serve as "red flags" for underlying genetic disorders, raising suspicion and highlighting the need for genetic counseling.

Identifying a relevant genetic background can improve medication safety, and expanding pharmacogenetic testing in ADR evaluation will have several benefits.

1. It will lead to new clinical diagnoses of previously unrecognized conditions.
2. It will enhance the safety and effectiveness of treatment, particularly for pediatric and elderly patients.
3. It will enable the repositioning of existing drugs for new therapeutic applications, particularly in rare diseases.
4. It will drive the development of new drugs tailored to specific genetic profiles.

Advanced laboratory techniques and artificial intelligence integration could lead to personalized medicine, predicting adverse drug reactions (ADRs), selecting appropriate drugs and dosages, and repurposing existing drugs for rare diseases.

REFERENCES

1. Bouvy, J. C., De Bruin, M. L., and Koopmanschap, M. A. (2015). Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 38 (5), 437–453. doi:10.1007/s40264-015-0281-0
2. Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., et al. (2011). Pharmacogenetics: from bench to byte- an update of guidelines.

Clin. Pharmacol. Ther. 89 (5), 662–673. doi:10.1038/clpt.2011.34
3. García-González, X., Cabaleiro, T., María José, H., McLeod, H., Luis, A., and López-Fernández, L. A. (2016). Clinical implementation of pharmacogenetics. Drug Metab. Personalized Ther. 31 (1), 9–16. doi:10.1515/dmpt-2015-0031
4. Weitzel, K. W., Cavallari, L. H., and Lesko, L. J. (2017). Preemptive panel-based pharmacogenetic testing: the time is now. Pharm. Res. 34 (8), 1551–1555. doi:10.1007/s11095-017-2163-x
5. Wilke, R. A., Lin, D. W., Roden, D.M., Watkins, P. B., Flockhart, D., Zineh, I., et al. (2007). Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6 (11), 904–916. doi:10.1038/nrd2423
6. Martinez-Matilla, M., Blanco-Verea, A., Santori, M., Ansede-Bermejo, J., Ramos-Luis, E., Gil, R., et al. (2019). Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths. Forensic Sci. Int. Genet. 42, 203–212. doi:10.1016/j.fsigen.2019.07.010
7. Dresser, G. K., Spence, J. D., and Bailey, D. G. (2000). Pharmacokinetic pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38 (1), 41–57. doi:10.2165/00003088-200038010-00003
8. Schaik, R. H. N. V., Müller, D. J., Serretti, A., and Ingelman-Sundberg, M. (2020). Pharmacogenetics in psychiatry: an update on clinical usability. Front. Pharmacol. 11, 575540. doi:10.3389/fphar.2020.575540
9. Sultana, J., Cutroneo, P., and Trifirò, G. (2013). Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 4 (Suppl. 1), S73–S77.doi:10.4103/0976-500x.120957
10. International Drug Monitoring: The Role of National Centres(1972). Report of a WHO Meeting World Health Organization Technical Report Series 498, 1–25.
11. Sakaeda, T., Tamon, A., Kadoyama, K., and Okuno, Y. (2013). Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10 (7), 796–803. doi:10.7150/ijms.6048
12. Afsar, N. A., Bruckmueller, H., Werk, A. N., KashifNisar, M., Ahmad, H. R., and Cascorbi, I. (2019). Implications of genetic variation of common drug metabolizing enzymes and ABC transporters among the Pakistani population. Sci. Rep. 9 (1), 7323. doi:10.1038/s41598-019-43736-z
13. Karki, R., Pandya, D., Elston, R. C., and Ferlini, C. (2015). 'Defining "mutation" and "polymorphism" in the era of personal genomics'. BMC Med. Genomics
14. Mehrotra, N., Gupta, M., Kovar, A., and Meibohm, B. (2007). The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int. J. Impot Res. 19 (3), 253–264. doi:10.1038/sj.ijir.3901522
15. Talal, A. H., Venuto, C. S., and Younis, I. (2017). Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment. Clin. Pharmacol. Drug Develop. 6 (2), 206–212. doi:10.1002/cpdd.336
16. Wardlaw, S., Nikula, K. J., Kracko, D. A., Finch, G. L., Thornton-Manning, J. R., and Dahl, A. R. (1998). Effect of cigarette smoke on CYP1A1, CYP1A2 and CYP2B1/2 of nasal mucosae in F344 rats. Carcinogenesis. 19 (4), 655–662. doi:10.1093/carcin/19.4.655
17. Chung, W. H., Wang, C. W., and Dao, R. L. (2016). Severe Cutaneous Adverse Drug Reactions. J. Dermatol. 43 (7), 758–766. doi:10.1111/1346-8138. 13430
18. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., et al. (2004). Medical Genetics: aMarker for Stevens-Johnson Syndrome. Nature 428 (6982), 486. doi:10.1038/428486a
19. Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., et al. (2006). Genetic Susceptibility to Carbamazepine-Induced Cutaneous Adverse Drug Reactions. Pharmacogenet Genomics 16 (4), 297–306. doi:10.1097/01.fpc.0000199500.46842.4a
20. Mehta, T. Y., Prajapati, L. M., Mittal, B., Joshi, C. G., Sheth, J. J., Patel, D. B., et al. (2009). Association of HLA-B*1502 Allele and Carbamazepine-Induced Stevens-Johnson Syndrome Among Indians. Indian J. Dermatol. Venereol. Leprol. 75 (6), 579–582. doi:10.4103/0378-6323.57718

21. Cheung, Y. K., Cheng, S. H., Chan, E. J., Lo, S. V., Ng, M. H., and Kwan, P. (2013). HLA-B Alleles Associated with Severe Cutaneous Reactions to Antiepileptic Drugs in Han Chinese. Epilepsia 54 (7), 1307–1314. doi:10.1111/epi.12217
22. Genin, E., Chen, D. P., Hung, S. I., Sekula, P., Schumacher, M., Chang, P. Y., et al. (2014). HLA-A*31:01 and Different Types of Carbamazepine-Induced Severe Cutaneous Adverse Reactions: an International Study and Meta-Analysis. Pharmacogenomics J. 14 (3), 281–288. doi:10.1038/tpj.2013.40
23. Kang, H. R., Jee, Y. K., Kim, Y. S., Lee, C. H., Jung, J. W., Kim, S. H., et al. (2011). Positive and Negative Associations of HLA Class I Alleles with Allopurinol-Induced SCARs in Koreans. Pharmacogenet Genomics 21 (5), 303–307. doi:10.1097/FPC.0b013e32834282b8
24. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., et al. (2002). Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir. Lancet 359 (9312), 1121–1122. doi:10.1016/S0140-6736(02)08158-8
25. Ueta,M., Nakamura, R., Saito, Y., Tokunaga, K., Sotozono, C., Yabe, T., et al. (2019). Association of HLA Class I and II Gene Polymorphisms with Acetaminophen-Related Stevens-Johnson Syndrome with Severe Ocular Complications in Japanese Individuals. Hum. Genome 6, 50. doi:10.1038/s41439-019-0082-6
26. Nakamura, R., Ozeki, T., Hirayama, N., Sekine, A., Yamashita, T., Mashimo, Y., et al. (2020). Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. J. Invest. Dermatol. 140 (8),1659–e6. doi:10.1016/j.jid.2019.12.025
27. Hautekeete, M. L., Horsmans, Y., Van Waeyenberge, C., Demanet, C., Henrion, J., Verbist, L., et al. (1999). HLA Association of Amoxicillin-Clavulanate-Iinduced Hepatitis. Gastroenterology 117 (5), 1181–1186. doi:10.1016/s0016-5085(99) 70404-x
28. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., et al. (2009). HLA-B*5701 Genotype Is a Major Determinant of Drug-Induced Liver Injury Due to Flucloxacillin. Nat. Genet. 41 (7), 816–819. doi:10.1038/ng.379
29. Nebert, D. W., and Russell, D. W. (2002). Clinical Importance of the Cytochromes P450. Lancet 360 (9340), 1155–1162. doi:10.1016/S0140-6736(02)11203-7
30. Yee, J., Heo, Y., Kim, H., Yoon, H. Y., Song, G., and Gwak, H. S. (2021). Association between the CYP2C9 Genotype and Hypoglycemia Among Patients with Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-Analysis. Clin. Ther. 43 (5), 836–e4. doi:10.1016/j.clinthera.2021.03.008
31. Fabbri, C., Tansey, K. E., Perlis, R. H., Hauser, J., Henigsberg, N., Maier, W., et al. (2018). Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-wide Association Studies. Eur. Neuropsychopharmacol. 28 (8), 945–954. doi:10.1016/j.euroneuro.2018.05.009
32. Banerjee, R., Ravikanth, V. V., Pal, P., Bale, G., Avanthi, U. S., Goren, I., et al. (2020). NUDT15 C415T Variant Compared with TPMT Genotyping in Predicting Azathioprine-Induced Leucopenia: Prospective Analysis of 1014 Inflammatory Bowel Disease Patients in India. Aliment. Pharmacol. Ther. 52 (11-12), 1683–1694. doi:10.1111/apt.16137
33. International Transporter, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., et al. (2010). Membrane Transporters in Drug Development. Nat. Rev. Drug Discov. 9 (3), 215.. doi:10.1038/nrd3028
34. Doss Priya, C. G., Alasmar, D. R., Bux, R. I., Sneha, P., Bakhsh, F. D., Al-Azwani, I., et al. (2016). Genetic epidemiology of glucose-6-phosphate dehydrogenase deficiency in the Arab world. Sci. Rep. 6, 37284. doi:10.1038/srep37284
35. Durrani, J., Awada, H., Shen, W., Kerr, C. M., Adema, V., Kongkiatkamon, S., et al. (2019). FA gene carrier status predisposes to myeloid neoplasms and bone marrow failure in adults. Blood 134 (Suppl. 1), 452. doi:10.1182/blood-2019-130142
36. Fan, W. L., Shiao, M. S., Hui, R. C., Su, S. C., Wang, C. W., Chang, Y. C., et al. (2017). HLA association with drug-induced adverse reactions. J. Immunol. Res. 2017, 3186328. doi:10.1155/2017/3186328

37. Lombardi, A., Inabnet, W. B., Owen, R., Farenholtz, K.E., Farenholtz, K. E., and Tomer, Y. (2015). Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis. J. Clin. Endocrinol. Metab. 100 (1), E1–E10. doi:10.1210/jc.2014-2745
38. Chakera, A. J., Steele, A. M., Gloyn, A. L., Gloyn, A. L., Shepherd,M. H., Shields, B., et al. (2015). Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Dia Care 38 (7), 1383–1392. doi:10.2337/dc14-2769
39. Locati, E. T., Bagliani, G., and Padeletti, L. (2017). Normal ventricular repolarization and QT interval. Card. Electrophysiol. Clin. 9 (3), 487–513. doi:10.1016/j.ccep.2017.05.007
40. Wong, J. C., Thelin, J. T., and Escayg, A. (2019). Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome. Ann. Clin. Transl Neurol. 6 (8), 1566–1571. doi:10.1002/acn3.50848
41. Ba, H. l., Mbatchi, L., Gattacceca, F., Evrard, A., Lacarelle, B., Blanchet, B., et al. (2020). Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after Sorafenib intake. Pharmacogenomics. 21 (3), 173–179. doi:10.2217/pgs-2019-0127
42. Zhu, J., Klein-Fedyshin, M., and Stevenson, J. M. (2017). Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence. Pharmacotherapy 37 (9), 1089–1104. doi:10.1002/phar.1978
43. Ciconte,G., Santinelli,V., Brugada, J.,Vicedomini,G.,Conti,M., Monasky, M.M., et al. (2018). General anesthesia attenuates Brugada syndrome phenotype expression. JACC: Clin. Electrophysiol. 4 (4), 518–530. doi:10.1016/j.jacep.2017.11.013
44. Pappone, C., and Santinelli, V. (2019). Brugada syndrome: progress in diagnosis and management. ArrhythmElectrophysiol. Rev. 8 (1), 13–18. doi:10.15420/aer.2018.73.2
45. Curtis, A. B., and Narasimha, D. (2012). Arrhythmias in women. Clin. Cardiol. 35 (3), 166–171. doi:10.1002/clc.21975